Related Experiment Videos
Thrombolysis for acute myocardial infarction
1Coronary Care Unit, Green Lane Hospital, Auckland, New Zealand. harveyw@ahsl.co.nz
Insights
Thrombolytic therapy for acute myocardial infarction is underused. Improving reperfusion rates through new agents and strategies can enhance patient outcomes and survival.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy is a key treatment for acute myocardial infarction (MI).
- Current thrombolytic regimens are underutilized and often delayed.
- Effective reperfusion is crucial for reducing infarct size and improving survival.
Purpose of the Study:
- To review current thrombolytic therapy for acute MI.
- To discuss strategies for improving reperfusion rates and patient outcomes.
- To highlight the importance of timely administration of thrombolytic therapy.
Main Methods:
- Review of existing literature on thrombolytic therapy for acute MI.
- Analysis of current treatment guidelines and clinical trial data.
- Discussion of potential improvements in thrombolytic agents and adjunctive therapies.
Main Results:
- Effective thrombolytic regimens achieve infarct artery patency in approximately 50% of patients within 90 minutes.
- Bleeding complications occur in ~5% and stroke in ~1.8% of patients.
- Ongoing clinical trials are exploring novel agents and combination therapies.
Conclusions:
- Timely administration of thrombolytic therapy is critical for patients with acute MI.
- Improving reperfusion rates through optimized dosing, combination therapy, or novel agents is essential.
- Further research and clinical trials are needed to enhance the efficacy and safety of thrombolytic therapy.
Abstract:
Thrombolytic therapy has been a major advance in the management of acute myocardial infarction. Unfortunately, it continues to be underused or is administered later than is optimal. Thrombolytic therapy works by lysing infarct artery thrombi and achieving reperfusion, thereby reducing infarct size, preserving left ventricular function, and improving survival. The most effective thrombolytic regimens achieve angiographic epicardial infarct-artery patency in only approximately 50% of patients within 90 minutes. Bleeding requiring transfusion occurs in approximately 5% of patients and stroke in approximately 1.8% with these regimens, which include adjunctive aspirin and intravenous heparin. There are several ways in which reperfusion rates and thus patient outcomes might be improved, such as different dosing regimens of established agents; combinations of different agents; improved adjunctive therapy such as direct antithrombin agents, low-molecular-weight heparin, or glycoprotein IIb/IIIa receptor antagonists; or the development of novel thrombolytic agents with enhanced fibrin specificity, resistance to native inhibitors, or prolonged half-lives allowing bolus administration. All of these strategies are being tested in clinical trials. The best approach currently is to administer thrombolytic therapy as soon as possible to all patients without contraindications who present within 12 hours of symptom onset and have ST-segment elevation on the ECG or new-onset left bundle-branch block, unless an alternative reperfusion strategy is planned.